THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM

被引：1
|
作者：
Schroeder, M. [1 ]
Johansen, P. [2 ]
Thompson, G. [1 ]
Willis, M. [3 ]
Neslusan, C. [4 ]
机构：
[1] Hanssen Ciiag UK, High Wycombe, Bucks, England
[2] Swedish Inst Hlth Econ IHE, Lund, Sweden
[3] Swedish Inst Hlth Econ, Lund, Sweden
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.694
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB71
引用
收藏
页码：A344 / A344
页数：1
相关论文
共 50 条
  • [41] Effects of Canagliflozin (CANA) on Biomarkers of Cardiovascular (CV) Stress in Older Patients with Type 2 Diabetes Mellitus (T2DM)
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Merton, Katherine W.
    Ren, Jimmy
    Canovatchel, William
    Desai, Mehul
    Davies, Michael J.
    DIABETES, 2017, 66 : LB40 - LB40
  • [42] IMPACT OF WEIGHT-RELATED UTILITIES ON THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [43] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [44] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    DIABETES, 2016, 65 : A308 - A308
  • [45] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [46] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [47] Canagliflozin (CANA) Improves Glycemic Control and Reduces Body Weight and Blood Pressure (BP) in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) With or Without Other Antihyperglycemic Agents (AHAs)
    Hollander, Priscilla
    Mathieu, Chantal
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    DIABETES, 2015, 64 : A662 - A663
  • [48] Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
    Gu, Shuyan
    Mu, Yiming
    Zhai, Suodi
    Zeng, Yuhang
    Zhen, Xuemei
    Dong, Hengjin
    PLOS ONE, 2016, 11 (11):
  • [49] Retrospective study of type 2 diabetes mellitus (T2DM) patients not optimally controlled by metformin monotherapy
    He, J.
    Neslusan, C.
    VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
  • [50] Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus
    Shao, Hui
    Zhai, Suodi
    Zou, Dajin
    Mir, Mohammed Umer
    Zawadzki, Nadine K.
    Shi, Qian
    Liu, Shuqian
    Shi, Lizheng
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (02) : 359 - 369
12345